What is Innovent Biologics Price-to-Free-Cash-Flow?
As of today (2024-05-28), Innovent Biologics's share price is HK$36.80.
Innovent Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.88. Hence, Innovent Biologics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Innovent Biologics's Price-to-Free-Cash-Flow or its related term are showing as below:
HKSE:01801's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.53 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 2.80% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 16.30% per year.
During the past 8 years, Innovent Biologics's highest 3-Year average Free Cash Flow per Share Growth Rate was 10.20% per year. The lowest was -65.50% per year. And the median was -8.80% per year.
Innovent Biologics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Innovent Biologics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Innovent Biologics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Price-to-Free-Cash-Flow falls into.
Innovent Biologics's Share Price of today is HK$36.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Innovent Biologics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 